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Abstract Long-term therapy is often required for psori-
asis. This article reviews the most recent long-term
clinical data for biological agents that have been ap-
proved or for which late-stage development data have
been released for the treatment of patients with moder-
ate to severe plaque psoriasis. Eﬃcacy data are available
for up to ﬁve 12-week courses of alefacept (approxi-
mately 60 weeks of therapy), 36 months (144 weeks) of
continuous efalizumab, 48 weeks of continuous etaner-
cept, and 50 weeks of bimonthly inﬂiximab. Data
sources include publications, product labeling, and
posters presented at recent international scientiﬁc
meetings. Alefacept appears to continue to be eﬃcacious
over multiple treatment courses for some responsive
patients. The eﬃcacy of efalizumab achieved during the
ﬁrst 12–24 weeks of therapy appears to be maintained or
improved through at least 60 weeks of continuous
treatment. The eﬃcacy of etanercept appears to be
maintained through at least 48 weeks of continuous
treatment. Inﬂiximab demonstrates a high response rate
soon after initiation, which appears to be maintained
through 24 weeks but declines modestly with therapy
out to 50 weeks. After 48 weeks, approximately 60% of
efalizumab-treated and 45% of etanercept-treated pa-
tients remaining on therapy achieved ‡75% improve-
ment from baseline in Psoriasis Area and Severity Index,
as did 70.5% of inﬂiximab patients who did not miss
more than two infusions. Safety data suggest that these
agents may be used for long-term administration. Long-
term data from psoriasis trials continue to accumulate.
Recent data suggest that biological therapies have eﬃ-
cacy and safety proﬁles suitable for the long-term
treatment of patients with moderate to severe psoriasis.
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Introduction
Psoriasis is a chronic inﬂammatory, immune-mediated
disease characterized by periods of spontaneous remis-
sion and relapse [22]. Conventional nonbiological ther-
apies for moderate to severe psoriasis, such as
cyclosporine, methotrexate, and phototherapy, have
proved eﬀective in suppressing symptoms; and many
dermatologists have at least a decade of experience using
these treatment modalities [21]. Because of the chronic
nature of psoriasis, many patients require lifelong
symptom management. Conventional nonbiological
systemic therapies have been successfully used as con-
tinuous therapy in some patients for extended periods
(e.g., methotrexate); however, for some patients, the
long-term use of these agents may be limited by known
toxicities, including nephrotoxicity (cyclosporine) [21],
hepatotoxicity (methotrexate) [10], skin cancer (psora-
len-ultraviolet A phototherapy, or PUVA) [23], and
prolonged teratogenicity (oral retinoids) [5].
Current treatment guidelines recommend limiting the
administration of cyclosporine to short-term (3-month)
intermittent therapy or to no longer than 1–2 years
continuously [11], reducing the dosage and minimizing
lifetime exposure to methotrexate and ultraviolet irra-
diation [12, 27], and avoiding treatment with oral reti-
noids and several other conventional antipsoriatic
therapies in women of childbearing potential [4]. Avail-
able data suggest that, when used according to con-
temporary guidelines and with appropriate monitoring
for toxicity, conventional nonbiological treatments can
be reasonably safe and tolerable [29]. However, mini-
mizing toxicity while still providing continuous control
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sents a clinical challenge.
An improved understanding of the immunologic ba-
sis of psoriasis led to the development of several targeted
biological therapies that attempt to address the chal-
lenge of providing long-term continuous disease control.
The ﬁrst biological agent approved for the treatment of
adult patients with moderate to severe chronic plaque
psoriasis, alefacept (Amevive
 , Biogen Idec Inc.), is
currently registered for use in several countries, includ-
ing the United States but not the European Union (EU).
Two others, efalizumab (Raptiva
 , Genentech, Inc.;
Serono International S.A.) and etanercept (Enbrel
 ,
Amgen, Inc.; Wyeth Pharmaceuticals), are also regis-
tered for this indication in multiple countries, including
the EU and the United States. Another biological, inf-
liximab (Remicade
 , Centocor, Inc.; Schering-Plough
Corp.), has presented Phase III clinical trial data for the
treatment of psoriasis and recently became registered for
use in the EU. The clinical trials programs for these four
agents have demonstrated their safety and eﬃcacy in
patients with psoriasis over an initial period of several
months; longer-term results are now becoming available.
One other biological agent, adalimumab (Humira
 ,
Abbott Laboratories), is at an earlier stage of develop-
ment for psoriasis and has completed Phase II clinical
trials for the disease. This article reviews the latest
clinical data available regarding the long-term eﬃcacy of
these biological agents for treatment of psoriasis.
Alefacept
Alefacept is a fusion protein between human leukocyte
function-associated antigen-3 (LFA-3) and the human
IgG1 antibody Fc region. By binding to the CD2 antigen
on T cells, alefacept prevents T-cell activation and trig-
gers apoptosis, preferentially targeting memory-eﬀector T
cells [3]. Alefacept has been evaluated as a weekly intra-
venous (IV) 7.5-mg administration and as a weekly
intramuscular (IM) 15-mg injection (Amevive
  [alefacept]
prescribing information; Cambridge, Mass: Biogen, Inc.;
August 2004); however, only the IM dose is currently
available. The eﬃcacy and safety of a 12-week course of
weekly IM alefacept 15 mg were evaluated in a ran-
domized, placebo-controlled Phase III trial of adult pa-
tients with chronic plaque psoriasis [minimum of 10%
body surface area (BSA) aﬀected by psoriasis] [15]. Two
weeks after the treatment phase was completed (study
week 14), the Psoriasis Area and Severity Index (PASI)
improved by at least 75% from baseline (PASI-75) in
21% of the 166 patients who received alefacept 15 mg per
week, with 42% achieving at least a 50% improvement
from baseline (PASI-50) (Amevive
  [alefacept] prescrib-
ing information). This compares with rates of 5 and 18%,
respectively, for patients randomized to placebo (n=168;
P<0.001 for both comparisons). Mean percentage PASI
improvement from baseline for a course of alefacept
15-mg IM therapy is shown in Fig. 1.
Alefacept has demonstrated the longest psoriasis
remission times among biological agents for psoriasis.
Patients who achieved PASI-75 after a 12-week course
of alefacept 15 mg per week (n=54) maintained at least
a PASI-50 response for a median period of approxi-
mately 7 months [15]. Thus, the long-term use of alefa-
cept as a remittive therapy has been explored through
extension studies of additional treatment courses for
patients who were enrolled in alefacept IV or IM Phase
III trials. Eﬃcacy data have been presented for up to ﬁve
12-week courses of alefacept therapy (i.e., approximately
60 weeks of treatment), although PASI responses are
available for only the IV formulation [IM results were
provided using Physician’s Global Assessment (PGA)]
(A. Menter et al., unpublished data presented at the 63rd
Annual Meeting of the American Academy of Derma-
tology, 2005). The analyses were performed on the as-
treated patient population, and a patient was considered
a responder if he or she achieved a response anytime
during each 12-week treatment course. Using these cri-
teria, PASI-75 response rates for IV alefacept increased
from 29% during the ﬁrst course of therapy (n=521) to
54% during course 5 (n=39). PGA response rates for
the IM formulation increased from 21% of patients
classiﬁed as ‘‘clear’’ or ‘‘almost clear’’ during course 1
(n=457) to 41% during course 4 (n=100), but the re-
sponse rate decreased to less than 30% during course 5
(n=50).
Alefacept therapy appears to be well tolerated, even
with long-term use. The primary concern with alefacept
is T-lymphocyte depletion. Alefacept should not be ini-
tiated in patients with CD4
+ T-lymphocyte counts be-
low normal, and biweekly CD4
+ T-cell monitoring is
recommended during each treatment course (Amevive
 
[alefacept] prescribing information). Alefacept should be
withheld if T-cell counts fall below 250 cells/ll and
discontinued if they remain low for a month. Patients
treated with alefacept during Phase III trials demon-
strated a low incidence of malignancy, serious infections
requiring hospitalization, and hypersensitivity reactions
(Amevive
  [alefacept] prescribing information). The
integrated safety database for alefacept includes a total
of 1,869 alefacept-treated psoriasis patients and includes
patients who have received up to nine courses of alefa-
cept therapy (n=8) over a 5-year period. Despite the
paucity of data for multiple treatment courses, the
incidence of common adverse events (e.g., headache,
nasopharyngitis, inﬂuenza, upper respiratory tract
infection, and pruritus), serious adverse events, infec-
tions, malignancies, and autoantibody production ap-
peared to ﬂuctuate little with additional treatment,
although the safety of long-term alefacept therapy will
need to continue to be assessed.
Efalizumab
Efalizumab is a recombinant humanized monoclonal
IgG1 antibody against the a subunit (CD11a) of LFA-1,
8which modulates several key steps in the immuno-
pathogenesis of psoriasis, including initial T cell activa-
tion, traﬃcking from the circulation into psoriatic
lesions, and reactivation therein [13]. Multiple Phase III
clinical trials have demonstrated the eﬃcacy, safety, and
health-related quality-of-life (HRQOL) beneﬁts of
12 weeks of subcutaneous (SC) efalizumab therapy in
patients with moderate to severe chronic plaque psori-
asis [6, 16, 20, 24, 28]. As will be discussed later, avail-
able clinical data support the eﬃcacy of extending
efalizumab treatment beyond 12 weeks, as reﬂected in
the European guidelines (European Medicines Agency:
Raptiva [efalizumab] summary of product characteris-
tics; http://www.emea.eu.int/humandocs/Humans/EPAR/
Raptiva/raptiv/htm; 2005).
The Phase III study that served as the basis for
efalizumab labeling evaluated the eﬃcacy and safety of
efalizumab 1 mg/kg weekly [6]. A total of 556 adult
patients with moderate to severe chronic plaque psori-
asis (baseline PASI ‡12.0 and ‡10% BSA aﬀected) were
randomized to receive efalizumab (n=369) or placebo
(n=187) double-blind for 12 weeks; all patients were
then eligible to receive extended efalizumab open-label
treatment for an additional 12 weeks [19]. A signiﬁcant
efalizumab treatment eﬀect relative to placebo was
achieved at 12 weeks, and extended treatment conferred
additional clinical beneﬁt. Using an intent-to-treat
(ITT) analysis with the last observation carried forward
(LOCF) for patients with missing data, the percentage
of efalizumab-treated patients who achieved PASI-75
increased from 27% at week 12 (vs. 4% with placebo,
P<0.001) to 44% at week 24. Similarly, the percentage
of efalizumab-treated patients who achieved PASI-50
and PASI-90 increased from 59 to 67% and from 5 to
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Fig. 1 Mean percentage psoriasis area and severity index (PASI)
improvement from baseline in randomized placebo-controlled,
Phase III studies of biological agents for the treatment of psoriasis.
ETANERCEPT Results for etanercept 25 or 50 mg twice weekly
for 24 weeks [18]. Sample size at each PASI assessment was not
reported. EFALIZUMAB Results for the use of efalizumab 1 mg/
kg/week for 12 weeks followed by a 12-week open-label extension
phase [6, 19]. The eﬃcacy-evaluable population for this study
included all patients randomized to efalizumab treatment (n=369),
which diﬀers from other efalizumab trials (and those of the other
agents discussed) that include only patients who received at least 1
dose of the study drug. Following are the sample sizes at each PASI
assessment, represented by the data points. For efalizumab: week 0,
369; week 2, 357; week 4, 353; week 8, 352; week 12, 347; week 16,
322; week 20, 323; week 24, 312. For placebo: week 0, 187; week 2,
186; week 4, 184; week 8, 180; week 12, 175 [19]. ALEFACEPT
Alefacept results for the available 15-mg intramuscular (IM) dose
[15]. Drug was administered weekly for 12 weeks, followed by
observation for 12 weeks. In this study, 166 patients were
randomized to receive alefacept 15 mg IM and 168 patients to
receive placebo. Sample sizes at each PASI assessment were not
provided. Statistical comparisons were not reported. Note Data for
inﬂiximab were not available
915% at weeks 12 and 24, respectively. The mean per-
centage PASI improvement relative to baseline in-
creased from 52% at week 12 to 67% at week 24
(Fig. 1)[ 6, 19]. Mean percentage PASI improvement
appeared to increase throughout the 24-week duration
without any evidence of a plateau eﬀect. Two addi-
tional Phase III studies with similar placebo-controlled,
double-blind initial 12-week treatment periods support
the eﬃcacy and safety of efalizumab therapy over
24 weeks [16, 17].
An open-label Phase III study evaluated the eﬃcacy,
safety, and tolerability of up to 36 months of contin-
uous efalizumab treatment. At the time of this writing,
results through 60 weeks of the trial and through
27 months (108 weeks) of the trial have been published
[7, 9] and data through 36 months (144 weeks) have
been presented (A.B. Gottlieb et al., unpublished re-
sults reported at the 63rd annual meeting of the
American Academy of Dermatology, 2005). A total of
339 patients with moderate to severe plaque psoriasis
received weekly efalizumab 2 mg/kg for 12 weeks; of
the 308 patients who completed the initial treatment
period, 290 patients (94%) achieved PASI-50 or a static
Physician’s Global Assessment (sPGA) of mild, mini-
mal, or clear at week 12 and were allowed to receive
maintenance treatment with efalizumab 1 mg/kg per
week for up to 33 additional months (132 weeks) [7, 9].
At completion of the ﬁrst 12-week treatment period,
41% of patients achieved PASI-75. Preliminary results
showed that, by week 60, PASI-75 responses were ob-
served in 49% of the ITT population (n=339) and in
57% of patients (n=290, last observation carried for-
ward) who were analyzed by means of a maintenance
group analysis, which included only patients eligible to
receive continued efalizumab. An as-treated analysis
indicated that 64% of patients (n=228) achieved PASI-
75 at week 60 (PASI-75 results through week 48 are
shown in Fig. 2)[ 7]. Results in this trial support the
sustained eﬃcacy of up to 36 months of continuous
efalizumab treatment (A.B. Gottlieb et al., unpublished
results reported at the 63rd annual meeting of the
American Academy of Dermatology, 2005).
Some limitations of the 3-year study are noted. At
initiation of the trial, the label-supported dosage of
1 mg/kg had not been established; thus, a dosage of
2 mg/kg was administered during the initial 3-month
period. It was subsequently demonstrated that the safety
and eﬃcacy do not diﬀer for the 1- and 2-mg/kg doses
[16, 17]. In addition, although relatively few patients
were aﬀected ( £ 4%), a dose increase of up to 4 mg/kg
was allowed up through 15 months of the study. Use of
the LOCF procedure during analysis of ITT data might
introduce bias in the ﬁnal result; depending on the re-
sponse of the patient, the bias could overestimate or
underestimate the ﬁnal result.
Clinical trials have shown that efalizumab is generally
well tolerated and has a favorable safety proﬁle over an
initial 12-week treatment period [6, 16, 24, 28]. Results
of the extended studies described here support the con-
tinued safety and tolerability of efalizumab treatment
periods longer than 12 weeks [7, 9, 16, 17, 19]. The most
common adverse events associated with efalizumab
administration are acute ﬂulike symptoms (headache,
chills, fever, myalgia, vomiting, and nausea) observed
primarily following the ﬁrst two doses. After the third
and subsequent doses, the incidence of acute adverse
events in efalizumab-treated patients is comparable to
that observed in placebo recipients. The extended
treatment studies have shown that, with the exception of
an expected reduction in acute adverse events, the inci-
dence and intensity of adverse events during the second
and subsequent treatment periods are similar to those
observed during the ﬁrst 12 weeks. To date, no evidence
of cumulative or end-organ toxicity has been found with
efalizumab. Thrombocytopenia has been reported dur-
ing efalizumab clinical trials (Raptiva
  [efalizumab]
package insert; South San Francisco, Calif: Genentech,
Inc.; June 2005), and recently a statement about the
development of hemolytic anemia has been added to the
prescribing information (Raptiva
  [efalizumab] package
insert). Worsening of psoriasis and psoriasis variants has
been observed in 3% of efalizumab patients during
therapy (i.e., generalized inﬂammatory ﬂare), and in
14% of patients following abrupt discontinuation of
efalizumab (i.e., rebound) [1]. The likelihood of experi-
encing rebound was inversely related to the PASI re-
sponse at week 12; 72% of patients experiencing
rebound were nonresponders, and only 10% had
achieved PASI-75 [1]. New-onset or worsening arthritis
has been infrequently reported during clinical trials and
postmarketing (Raptiva
  [efalizumab] package insert).
Based on available clinical data from up to 36 months of
continuous treatment, efalizumab does not appear to be
associated with an increased risk of malignancy or
opportunistic infections observed in immunosuppressed
hosts [7, 16, 17, 19, 28]. Because the numbers of patients
evaluated in the long-term studies have been relatively
small, the incidence of malignancy and infection will be
assessed postmarketing (Raptiva
  [efalizumab] package
insert).
Etanercept
Etanercept is a recombinant fusion protein comprising
domains of the 75-kDa human tumor necrosis factor
(TNF) receptor and human IgG1, which inhibits the
activity of TNF-a, a proinﬂammatory cytokine impli-
cated in psoriasis. The eﬃcacy, safety, and HRQOL
beneﬁts of 12 and 24 weeks of etanercept therapy in
patients with moderate to severe chronic plaque psori-
asis (baseline PASI ‡10 and ‡10% of BSA aﬀected) have
been demonstrated in Phase III clinical trials [18, 25].
There is also clinical experience with etanercept in other
indications, such as rheumatoid arthritis (RA). Recom-
mended dosage in the EU is 25 mg administered SC
twice weekly for up to 24 weeks. Dosing at 50 mg twice
weekly is also possible for the ﬁrst 12 weeks followed by
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Fig. 2 Percentage of patients achieving 75% improvement from
baseline psoriasis area and severity index (PASI). Solid lines
indicate intention-to-treat analyses; broken lines indicate as-treated
analyses (efalizumab) or modiﬁed ITT analysis (inﬂiximab)
ETANERCEPT Results shown are from an etanercept study in
which patients received etanercept 25 mg (n=196), etanercept
50 mg (n=194), or placebo (n=193) twice weekly for 12 weeks
followed by open-label etanercept 25 mg twice weekly for up to 36
additional weeks [25]. Eﬃcacy was evaluated in the ITT
population. Published data beyond 24 weeks are not available;
however, the data presented at several international medical
congresses [e.g., European Academy of Dermatology and Vene-
reology (EADV), American Academy of Dermatology (AAD)]
suggest that the additional eﬃcacy initially achieved with
etanercept 50 mg twice weekly beyond that obtained with the
50-mg-per-week dose might not be sustained in the long term
following dose reduction (unpublished data presented at the 2004
EADV and 2005 summer AAD meetings). EFALIZUMAB
Results are shown for efalizumab from an open-label Phase III
study (n=339) of efalizumab 2 mg/kg/week for 12 weeks, fol-
lowed by 1 mg/kg/week for up to 33 additional months in patients
who achieved PASI-50 or a static Physician’s Global Assessment
(sPGA) of mild, minimal, or clear at week 12 [7]. The dosage
received during the ﬁrst 12 weeks was higher than that later
approved for clinical use (1 mg/kg/week). Eﬃcacy was evaluated
in the intent-to-treat (ITT) population throughout the study and
is presented through 48 weeks; as-treated analysis is shown after
12 weeks through week 48. Sample sizes for as-treated analysis are
as follows: week 24, 290; week 36, 269; week 48, 247 [7]. The
shaded portion speciﬁes a response window framed by the most
conservative measure of eﬃcacy (ITT) and the response of
patients that remain on therapy (as-treated). ALEFACEPT
Results are shown for alefacept 7.5 mg administered intravenously
(IV) (A. Menter et al., unpublished data presented at the 63rd
annual meeting of the American Academy of Dermatology); long-
term PASI-75 response rates for the alefacept intramuscular (IM)
dosing regimen have not been reported. Each course represents
12 weekly alefacept infusions followed by a minimum of 12 weeks
of treatment-free observation. The second course was initiated
12 weeks after the ﬁrst course [14]; additional treatment courses
were initiated when the patient was deemed by the investigator to
require systemic therapy or phototherapy for psoriasis recurrence.
Course 5 represents patients who may have received up to 60 total
weeks of alefacept treatment. Sample sizes are as-treated numbers.
INFLIXIMAB Results are shown for inﬂiximab patients who were
randomized to receive IV inﬂiximab 5 mg/kg or placebo at
initiation, week 2, week 6, and then every 8 weeks through week
46 [26]. Analyses through week 10 were performed using the ITT
population (inﬂiximab, n=301; placebo, n=77); analyses through
week 50 were based on a ‘‘modiﬁed ITT’’ population (n=234)
where missing data were considered as nonresponse for patients
who withdrew from the study due to preselected reasons (mainly
related to lack of eﬃcacy; patients who withdrew for other
reasons were omitted from the analysis)
11a ‘‘step-down’’ to 25 mg twice weekly. Based on pub-
lished clinical data, European guidelines indicate that
nonresponders should discontinue etanercept after
12 weeks and that reinitiation of etanercept treatment is
possible after discontinuation (European Medicines
Agency. Enbrel [etanercept] summary of product char-
acteristics; http://www.emea.eu.int/humandocs/Humans/
EPAR/enbrel/enbrel.htm; 2005). In the United States, a
50-mg preﬁlled syringe recently became available, and
the recommended dosing of etanercept is 50 mg twice
weekly for the ﬁrst 12 weeks of treatment, followed by
step-down to 50 mg once weekly (Enbrel
  [etanercept]
package insert; Thousand Oaks, Calif: Immunex Cor-
poration; October 2005).
A placebo-controlled, double-blind Phase III study
demonstrated the safety and eﬃcacy of 12 and 24 weeks
of etanercept treatment [18]. A total of 672 patients were
randomized 1:1:1:1 to receive placebo or etanercept
25 mg once weekly, 25 mg twice weekly, or 50 mg twice
weekly via SC injection for 12 weeks. Etanercept recip-
ients who completed the initial treatment period con-
tinued on their assigned dosage for an additional
12 weeks. Whereas eﬃcacy was originally reported only
in patients who received at least 1 dose of study drug
(n=652) [18], some data were subsequently reanalyzed
for all patients who were enrolled and randomized,
irrespective of whether the study drug was administered
(Enbrel
  [etanercept] package insert). These data are
discussed herein to allow for a more accurate compari-
son with ITT data from efalizumab clinical trials. This
reanalysis showed that among patients randomized to
receive etanercept 25 or 50 mg twice weekly (the dosages
most similar to those now recommended in Europe and
the United States), 32 and 47% of patients, respectively,
achieved PASI-75 at week 12, increasing to 41 and 54%
at week 24 (Enbrel
  [etanercept] package insert). The
mean percentage PASI improvement reported in pa-
tients who received at least 1 dose of etanercept 25 or
50 mg increased from 53 to 64%, respectively, at week
12 to 62 and 71% at week 24. However, it appears that
the mean percentage PASI improvement began to pla-
teau around week 20 (Fig. 1).
Results from the ﬁrst 24 weeks of a 48-week contin-
uous etanercept therapy global Phase III psoriasis study
were recently published. In the initial 12-week, placebo-
controlled, double-blind phase of the study, 611 patients
were randomized 1:1:1 to receive placebo or etanercept
25 or 50 mg twice weekly; all patients were then eligible
to receive open-label etanercept 25 mg twice weekly for
up to 36 additional weeks. Results at 12 and 24 weeks
were reported for all randomized patients who received
at least 1 dose of study drug (n=583) using the LOCF
procedure for analysis and for all randomized patients
regardless of whether they received study drug (n=611),
with the assumption that patients with missing data had
not met the criteria for response at that end point [25].
At 12 weeks, 32 and 46% of all patients randomized to
receive etanercept 25 or 50 mg twice weekly, respec-
tively, achieved PASI-75 (vs. 3% for placebo, P<0.0001
both comparisons). The PASI-75 response rate was
slightly higher among patients who received at least 1
dose of etanercept 25 or 50 mg (34 and 49%, respec-
tively), increasing to 45 and 54% at week 24 [25]. Data
presented for this study at scientiﬁc meetings [2004
meeting of the European Academy of Dermatology and
Venereology [EADV] and 2005 meeting of the American
Academy of Dermatology (AAD)] indicated that among
patients continuing on etanercept 25 mg twice weekly,
the PASI-75 response achieved at week 24 was main-
tained through week 48 of continuous treatment and
suggested that the greater PASI-75 response rate initially
observed after 24 weeks in the group initially random-
ized to etanercept 50 mg twice weekly decreased slightly
after per-protocol dose reduction, with PASI-75 re-
sponse rates reaching a similar level in both groups
during the open-label treatment phase (W. Sterry,
unpublished data).
A randomized, placebo-controlled, multicenter Phase
III study to evaluate the safety and eﬃcacy of etanercept
50 mg twice weekly over the course of 2 years is cur-
rently ongoing. Preliminary results after 48 weeks of
therapy were recently reported (S.K. Tyring et al.,
unpublished data presented at the summer meeting of
the American Academy of Dermatology, 2005). In this
trial, patients were randomized to receive either etaner-
cept 50 mg (n=311) or placebo twice weekly for
12 weeks (n=307), followed by open-label etanercept
50 mg twice weekly. Etanercept demonstrated statisti-
cally signiﬁcant improvements in PASI response rates
compared with placebo by week 4 of therapy. Response
rates continued to increase through 24 weeks of therapy,
after which they appeared to plateau. Approximately
60% of patients achieved a PASI-75 response at week
24, with a similar proportion at week 48.
Clinical data support the safety and tolerability of
12–24 weeks of etanercept treatment in patients with
psoriasis [18, 25]. Published results from psoriasis clini-
cal trials showed that etanercept was generally well
tolerated. Adverse events observed during the initial
12-week placebo-controlled period were typically mild to
moderate in intensity and occurred with similar fre-
quency in etanercept and placebo groups [18, 25]. No
apparent change in the adverse events proﬁle occurred
during the second 12-week period of the trials [18, 25].
Safety outcomes of the long-term Phase III psoriasis
clinical trial, particularly for patients who received
50 mg twice weekly, have not yet been presented in de-
tail; however, a preliminary analysis integrating data
from the Phase II and 2 Phase III etanercept clinical
trials, in which many patients received the 25-mg dosage,
suggested that no new pattern of adverse events emerged
during up to 60 weeks of treatment (A.B. Gottlieb et al.,
unpublished data presented at the 62nd annual meeting
of the American Academy of Dermatology, 2004).
Psoriasis clinical trials revealed no evidence of increased
risk of opportunistic infections, tuberculosis, or skin
cancers during up to 60 weeks of etanercept treatment
(A.B. Gottlieb et al., unpublished data, 2004). Whereas
12long-term data from clinical trials in many patients
receiving etanercept for other indications, such as RA,
support the general safety and tolerability of the 25-mg
dosage, there have been infrequent cases of tuberculosis
and rare cases of demyelinating disorders, pancytopenia,
and congestive heart failure (Enbrel
  [etanercept]
package insert, European Medicines Agency; Enbrel
[etanercept] summary of product characteristics; http://
www.emea.eu.int/humandocs/Humans/EPAR/enbrel/
enbrel.htm; 2005).
Inﬂiximab
Inﬂiximab, a chimeric monoclonal antibody that binds
membrane-bound and soluble TNF-a, is still under
evaluation for use in patients with psoriasis. Inﬂiximab
has demonstrated eﬃcacy in psoriasis patients in ran-
domized, placebo-controlled Phase II trials [2, 8].
However, the results of an international multicenter,
randomized, placebo-controlled Phase III trial of adult
patients with plaque psoriasis (baseline PASI ‡12 and
‡10% of BSA aﬀected) were recently reported [26]. Pa-
tients were randomized to receive IV inﬂiximab 5 mg/kg
(n=301) or placebo (n=77) at initiation, week 2, and
week 6 and then every 8 weeks through week 46. The
placebo group crossed over to inﬂiximab treatment at
week 24, but the study remained blinded throughout.
Patients who discontinued the study early because of
lack or loss of response or for whom insuﬃcient data
were available were treated as not achieving the end
points for analysis of the ITT population. At week 10 of
treatment, the PASI-75 response rate was 80.4% in the
inﬂiximab-treated group and 2.6% in the placebo-treated
group. This level of response was sustained through
week 24. At week 50, the proportion of the ITT popu-
lation that achieved PASI-75 dropped to 60.5%. How-
ever, excluding patients who missed 2 infusions, the
PASI-75 rate at week 50 was 70.5% (n=234). The rea-
son for the moderate reduction in eﬃcacy is unclear but
may be due to the development of inhibitory antibodies
in a percentage of the patients.
The safety proﬁle for inﬂiximab during this extended
treatment Phase III trial appears to be comparable
to those observed during earlier studies [26]. The inci-
dence of adverse events and serious adverse events in
inﬂiximab-treated patients was slightly elevated relative
to those in placebo recipients through the ﬁrst 24 weeks
of treatment, and one patient who received inﬂiximab
died of sepsis. Elevations in aminotransferases were
also observed in some inﬂiximab-treated patients. In
this trial, infection rates were comparable between the
treated and placebo groups; however, like etanercept,
postmarketing data from inﬂiximab-treated patients
with RA, Crohn’s disease, or other indications for
which inﬂiximab is approved suggest a potential in-
creased risk for events such as opportunistic infections
(e.g., tuberculosis), lymphoma, or congestive heart
failure.
Adalimumab
Adalimumab is a fully human monoclonal antibody that
binds TNF-a. It is currently being evaluated in Phase III
clinical studies for the treatment of moderate to severe
plaque psoriasis. Results from a Phase II randomized,
double-blind, placebo-controlled, multicenter clinical
trial have been presented (K.B. Gordon et al., unpub-
lished data presented at the 62nd annual meeting of the
American Academy of Dermatology, 2004). Patients
were randomized to receive placebo (n=52) or ada-
limumab, either an 80-mg ﬁrst dose followed by 40 mg
every other week (EOW; n=46) or an 80-mg ﬁrst and
second dose followed by 40 mg every week (n=50), for
12 weeks. In the preliminary analysis and presentation,
53 and 80% of the patients receiving adalimumab EOW
or every week, respectively, achieved a PASI-75 re-
sponse, compared to 4% of the patients receiving pla-
cebo (n=52). However, a careful reanalysis of the data
suggested that the true eﬃcacy was several percentage
points lower (R.G.B. Langley et al., unpublished data,
presented at the Fall European Academy of Dermatol-
ogy and Venereology, 2005). Adverse events were similar
to placebo, with headache, injection site pain, nausea,
elevated triglycerides, cough, sinus congestion, and fa-
tigue most common. Injection site pain was more fre-
quent in the adalimumab 40-mg/week group (12%) than
in the placebo group (6%).
Comparison of biological agents
In the absence of head-to-head clinical trials, it is diﬃ-
cult to accurately compare the eﬃcacy of the biological
agents for psoriasis. However, most of these agents use
comparable evaluations of treatment eﬃcacy. Alefacept
is an exception, as it is used as remittive therapy; and
alefacept data are presented using the as-treated popu-
lation and ‘‘response at any time’’ analyses. Thus, al-
though alefacept appears to maintain eﬃcacy in
responsive patients over multiple courses of treatment
(Fig. 2), its eﬃcacy cannot be readily compared with
efalizumab, etanercept, or inﬂiximab.
Available long-term data indicate that the improve-
ments in psoriasis achieved during the ﬁrst 12–24 weeks
of efalizumab therapy are maintained or improved
through at least 60 weeks of continuous treatment. Data
support the eﬃcacy of efalizumab through at least
36 months of continuous treatment. The eﬃcacy of
etanercept 25 mg administered twice weekly appears to
be maintained through at least 48 weeks of continuous
treatment. Preliminary ﬁndings of the PASI-75 response
rate in patients who ‘‘step down’’ from etanercept 50 mg
twice weekly to 25 mg twice weekly suggest that the
initial improvements achieved with etanercept 50 mg
twice weekly beyond what is observed with the 25-mg
twice-weekly dose are slightly reduced following the
recommended dose reduction. For inﬂiximab, the very
13high response rates obtained after 10 weeks of treatment
appear to be sustained through 24 weeks but show a
moderate reduction through 48 weeks with infusions
every 8 weeks. Week 48 PASI-75 response rates were
62% for efalizumab-treated patients and approximately
45% for etanercept-treated patients (as-treated popula-
tions; Fig. 2). The PASI-75 response rate at week 50 for
inﬂiximab was 70.5% in patients who did not miss more
than 1 infusion (Fig. 2).
The longer-term studies summarized here are not
directly comparable because of diﬀerences in patient
eligibility for initial enrollment and maintenance treat-
ment and inclusion in eﬃcacy analyses. For example, in
contrast to the long-term etanercept study, patients in
the efalizumab open-label trial were eligible for main-
tenance treatment only if they achieved a reasonable
response during the ﬁrst 12 weeks. This included the
majority (94%) of patients completing the initial
treatment phase. For the ITT eﬃcacy analyses (pre-
sented through 12 weeks), all efalizumab-treated pa-
tients were included, even those who did not achieve
PASI-50 or sPGA of mild, minimal, or clear at week 12
and were required to discontinue the trial. Direct data
comparisons are further compromised by the available
analyses. Efalizumab data are presented as both an ITT
analysis for 48 weeks and an as-treated analysis for
weeks 12 through 48. Etanercept data are presented as
an ITT analysis through 48 weeks. Results from the
long-term inﬂiximab study are presented as an ITT
analysis for the ﬁrst 10 weeks of the trial and thereafter
are presented as a ‘‘modiﬁed ITT’’ population, where
missing data were considered as nonresponsive for pa-
tients who withdrew from the study for preselected
reasons.
Given that psoriasis is a chronic, incurable disease,
the availability of long-term data is critical for derma-
tologists evaluating treatment options. There is a pau-
city of long-term data derived from robust clinical trials
for conventional nonbiological psoriasis therapies;
therefore, dermatologists generally rely on treatment
guidelines and personal experience in making their
decisions about long-term administration of therapies
such as methotrexate and cyclosporine. Because bio-
logicals represent a new approach to the management
of psoriasis, long-term data are of particular impor-
tance for this therapeutic class. Alefacept appears to be
an eﬀective therapy for inducing extended remissions in
a small population of patients, and it has a demon-
strated safety proﬁle for remittive use. The long-term
data available to date for efalizumab indicate that ini-
tial improvements in psoriasis are sustained for up to
36 months. Data from multiple clinical trials indicate
that 22–41% of patients achieved PASI-75 in the ﬁrst
3 months of therapy [6, 7, 16, 17, 24]; in an extended
trial of patients receiving continuous therapy up to
36 months, 45.4% of the patients achieved PASI-75 at
the 36-month end point (C.L. Leonardi et al., manu-
script in preparation). Studies evaluating the long-term
use of etanercept are under way, but only limited data
are currently available, as suggested by the current
24-week limit for etanercept therapy in Europe. At
12 weeks, 49% of patients who received etanercept
50 mg twice weekly achieved PASI-75 [25]. Available
data suggest that improvements are maintained for
48 weeks, as 60% of patients receiving 50 mg twice
weekly achieved PASI-75 (S.K. Tyring et al., unpub-
lished data presented at the summer meeting of the
American Academy of Dermatology, 2005). Impor-
tantly, the safety data reported to date indicate that the
safety proﬁles of efalizumab and etanercept allow for
continuous long-term administration. Inﬂiximab has
demonstrated excellent response rates with induction
and extended therapy, with an every-8-week infusion
schedule optimal.
The approval of biological therapies, that is, the
T-cell-modulators alefacept and efalizumab and the
TNFa antagonist etanercept, along with the develop-
ment of other TNFa antagonists such as inﬂiximab and
adalimumab, represent signiﬁcant advances for the
management of psoriasis. Their eﬃcacy and safety pro-
ﬁles suggest that they may be suitable for remittive or
continuous long-term administration, providing derma-
tologists with new options for the long-term manage-
ment of their patients with psoriasis. The safety and
eﬃcacy data from ongoing clinical trials and the expe-
rience of dermatologists are important to deﬁne further
how these agents can best be integrated into the psoriasis
armamentarium.
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